Evan Lockwood Rachlin
Director · Iambic Therapeutics, Inc.
IndividualBuying only
- 2026
- Oct 19, 2026
- 2
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Evan Lockwood Rachlin's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- TC Group VII S1, L.L.C. - $554.95M in MDLN purchases and sales in the last 12 months
- BERKSHIRE HATHAWAY INC - $473.67M in DVA purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $430.69M in PBLS purchases and sales in the last 12 months
- Fairmount Funds Management LLC - $399.66M in SYRE purchases and sales in the last 12 months
- Robert M. Williams Jr. - $371.84M in AVAH purchases and sales in the last 12 months
- Paul R. Vigano - $371.84M in AVAH purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Evan Lockwood Rachlin?
Evan Lockwood Rachlin is a corporate insider, tracked as Director of Iambic Therapeutics, Inc. (IAM). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Evan Lockwood Rachlin submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Evan Lockwood Rachlin been buying or selling stock?
Recorded transactions: 1 open-market purchase ($11.50M) and 0 open-market sales across all tracked filings.
